PL2417107T3 - Krystaliczne postacie saksagliptyny - Google Patents

Krystaliczne postacie saksagliptyny

Info

Publication number: PL2417107T3
Authority: PL; Poland
Prior art keywords: saxagliptin; crystal forms; crystal; forms
Prior art date: 2009-04-09

Application number

PL10713211T

Other languages

English (en)

Inventor

Arthur Pichler

Josef Wieser

Christoph Langes

Milica Vukicevic

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-04-09

Filing date

2010-04-09

Publication date

2016-02-29

2010-04-09 Application filed by Sandoz Ag filed Critical Sandoz Ag

2016-02-29 Publication of PL2417107T3 publication Critical patent/PL2417107T3/pl

Links

239000013078 crystal Substances 0.000 title 1
QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 title 1
229960004937 saxagliptin Drugs 0.000 title 1
108010033693 saxagliptin Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

PL10713211T 2009-04-09 2010-04-09 Krystaliczne postacie saksagliptyny PL2417107T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US16791809P	2009-04-09	2009-04-09
EP09157723		2009-04-09
EP09175259		2009-11-06
PCT/EP2010/054692 WO2010115974A1 (en)	2009-04-09	2010-04-09	Crystal forms of saxagliptin
EP10713211.0A EP2417107B1 (en)	2009-04-09	2010-04-09	Crystal forms of saxagliptin

Publications (1)

Publication Number	Publication Date
PL2417107T3 true PL2417107T3 (pl)	2016-02-29

Family

ID=42935672

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL10713211T PL2417107T3 (pl)	2009-04-09	2010-04-09	Krystaliczne postacie saksagliptyny

Country Status (12)

Country	Link
US (2)	US20120088808A1 (pl)
EP (1)	EP2417107B1 (pl)
JP (2)	JP6088245B2 (pl)
KR (1)	KR20120006047A (pl)
CN (2)	CN102459170B (pl)
AU (1)	AU2010233718B2 (pl)
BR (1)	BRPI1006547A2 (pl)
CA (1)	CA2757934C (pl)
ES (1)	ES2548386T3 (pl)
PL (1)	PL2417107T3 (pl)
RU (1)	RU2539590C2 (pl)
WO (1)	WO2010115974A1 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0487425A (ja) *	1990-07-31	1992-03-19	Fujitsu Ltd	回線切り替え装置
AU2010233718B2 (en) *	2009-04-09	2015-11-05	Sandoz Ag	Crystal forms of Saxagliptin
ES2546866T3 (es) *	2009-12-16	2015-09-29	Hetero Research Foundation	Polimorfos de darunavir
EP2571355B1 (en)	2010-05-20	2016-09-07	Hetero Research Foundation	Crystalline hydrochloride salt of darunavir
US8410288B2 (en)	2010-10-04	2013-04-02	Teva Pharmaceutical Industries Ltd.	Polymorphs of Saxagliptin hydrochloride and processes for preparing them
EP2753328A1 (en)	2011-09-07	2014-07-16	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	Dpp-iv inhibitor formulations
PL2578208T3 (pl)	2011-10-06	2014-10-31	Sanovel Ilac Sanayi Ve Ticaret As	Stałe formulacje dawkowane inhibitora DPP-IV
WO2013136343A1 (en)	2012-03-12	2013-09-19	Mylan Laboratories Ltd.	Amorphous saxagliptin hydrochloride
EP2841419A1 (en) *	2012-04-25	2015-03-04	Enantia, S.L.	Crystalline forms of saxagliptin
US9994523B2 (en)	2012-05-24	2018-06-12	Apotex Inc.	Salts of Saxagliptin with organic acids
EP2867206A2 (en)	2012-07-02	2015-05-06	Ranbaxy Laboratories Limited	Saxagliptin salts
WO2015067223A1 (en)	2013-11-06	2015-05-14	Zentiva, K., S.	L-tartrate salt of (1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl) acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile and process for preparation thereof
JP2022182181A (ja) *	2021-05-27	2022-12-08	キョーリンリメディオ株式会社	ビルダグリプチン含有医薬品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6032616B2 (ja) *	1976-08-24	1985-07-29	アレクサンダ− ガラツト	高い貯蔵安定性の無水アセチルサリチル酸ナトリウム
US6395767B2 (en) *	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US7420079B2 (en) *	2002-12-09	2008-09-02	Bristol-Myers Squibb Company	Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
US6995183B2 (en) *	2003-08-01	2006-02-07	Bristol Myers Squibb Company	Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
TWI415635B (zh) *	2004-05-28	2013-11-21	必治妥施貴寶公司	加衣錠片調製物及製備彼之方法
WO2006008641A1 (en) *	2004-07-16	2006-01-26	Warner-Lambert Company Llc	Hair growth promoting agents
US20060035954A1 (en) *	2004-08-11	2006-02-16	Sharma Padam N	Ammonolysis process for the preparation of intermediates for DPP IV inhibitors
PE20090696A1 (es) *	2007-04-20	2009-06-20	Bristol Myers Squibb Co	Formas cristalinas de saxagliptina y procesos para preparar las mismas
AU2010233718B2 (en) *	2009-04-09	2015-11-05	Sandoz Ag	Crystal forms of Saxagliptin

2010
- 2010-04-09 AU AU2010233718A patent/AU2010233718B2/en not_active Ceased
- 2010-04-09 CA CA2757934A patent/CA2757934C/en not_active Expired - Fee Related
- 2010-04-09 BR BRPI1006547A patent/BRPI1006547A2/pt not_active Application Discontinuation
- 2010-04-09 CN CN201080025360.7A patent/CN102459170B/zh not_active Expired - Fee Related
- 2010-04-09 KR KR1020117026595A patent/KR20120006047A/ko not_active Abandoned
- 2010-04-09 JP JP2012504028A patent/JP6088245B2/ja not_active Expired - Fee Related
- 2010-04-09 US US13/262,652 patent/US20120088808A1/en not_active Abandoned
- 2010-04-09 WO PCT/EP2010/054692 patent/WO2010115974A1/en not_active Ceased
- 2010-04-09 PL PL10713211T patent/PL2417107T3/pl unknown
- 2010-04-09 RU RU2011145054/04A patent/RU2539590C2/ru not_active IP Right Cessation
- 2010-04-09 EP EP10713211.0A patent/EP2417107B1/en not_active Not-in-force
- 2010-04-09 CN CN201410283458.2A patent/CN104016902B/zh not_active Expired - Fee Related
- 2010-04-09 ES ES10713211.0T patent/ES2548386T3/es active Active
2013
- 2013-10-02 US US14/044,204 patent/US9260389B2/en active Active
2015
- 2015-07-16 JP JP2015141890A patent/JP2016006063A/ja active Pending

Also Published As

Publication number	Publication date
CA2757934C (en)	2017-12-19
BRPI1006547A2 (pt)	2016-10-18
EP2417107B1 (en)	2015-08-26
KR20120006047A (ko)	2012-01-17
WO2010115974A1 (en)	2010-10-14
EP2417107A1 (en)	2012-02-15
JP2016006063A (ja)	2016-01-14
ES2548386T3 (es)	2015-10-16
US20120088808A1 (en)	2012-04-12
CN104016902A (zh)	2014-09-03
AU2010233718B2 (en)	2015-11-05
US20140200252A1 (en)	2014-07-17
AU2010233718A1 (en)	2011-10-27
CN102459170B (zh)	2014-07-23
JP2012523395A (ja)	2012-10-04
CN104016902B (zh)	2017-10-20
JP6088245B2 (ja)	2017-03-01
US9260389B2 (en)	2016-02-16
CA2757934A1 (en)	2010-10-14
RU2539590C2 (ru)	2015-01-20
CN102459170A (zh)	2012-05-16
RU2011145054A (ru)	2013-05-20

Publication	Publication Date	Title
HUS1800015I1 (hu)	2018-05-28	Kristályok
AU327459S (en)	2009-09-03	Watch
ZA201304280B (en)	2014-08-27	Treatment of jak2-mediated conditions
EP2435390A4 (en)	2014-05-07	TRANSALCYLATION OF POLYCYCLOHEXYLBENZENES
EP2438246A4 (en)	2014-11-12	CONSTRUCTION ASPECTS
GB0920382D0 (en)	2010-01-06	Design of molecules
IL196456A0 (en)	2009-12-24	Uderbelly of armord vehicle
GB0915515D0 (en)	2009-10-07	Treatment of vasculoproliferative conditions
ZA201200783B (en)	2012-10-31	Crystal modification of mesotrione
IL206491A0 (en)	2010-12-30	Treatment of produce
AU327584S (en)	2009-09-14	Watch
AU332426S (en)	2010-08-31	Watch
PL2493496T3 (pl)	2017-03-31	Zastosowanie GSTP1
GB0908006D0 (en)	2009-06-24	New crystal form
GB0908101D0 (en)	2009-06-24	Treatment of stress
EP2459540A4 (en)	2012-12-19	PREPARATION OF FIPAMEZOLE
EP2379502A4 (en)	2012-06-27	NOVEL FORMS OF EPERISON
TWM372743U (en)	2010-01-21	Improved structure of Kendama
TWM365675U (en)	2009-10-01	Improved structure of teapoy
TWM372203U (en)	2010-01-11	Structure of goggles
TWM374127U (en)	2010-02-11	Structure of three-string Huqin
GB0905280D0 (en)	2009-05-13	Novel uses of VEGFxxxb
GB2464599B (en)	2010-09-08	Attachment of can ends
AU328528S (en)	2009-11-18	Wristwatch
TWM370387U (en)	2009-12-11	Structure of tongue-scraping device